Skip to main content

Current and Alumni Fellows

Get to know our current fellows, and learn how IOTF is helping them achieve their professional goals in oncology product research and regulatory review. A list of all alumni fellows can be found below.

Current Fellows

Learn more about the experiences and research interests of our current fellows.

Jessica Eisenstatt, Ph.D.

The IOTF fellowship has provided a unique opportunity to shift focus from basic research to regulatory-driven research and product development. The seminars and trainings allow you to dive into the regulatory review process and the scientific research conducted at the FDA and to see how interconnected the two are. Working one-on-one with an experienced mentor provides a hands-on opportunity to learn how to review documents. During the review process, you can also interact with other experts at the FDA, which will help to build your knowledge of new topics and your network. The fellowship is an excellent experience for someone looking to continue to be engaged in novel scientific approaches and to learn about the drug development review process.

Dr. Eisenstatt received her Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, OH. She went on to perform her postdoctoral work in the Genetics Branch at the National Cancer Institute, National Institutes of Health. Dr. Eisenstatt joined the NCI-FDA Interagency Oncology Task Force Fellowship in September 2020 and is working as a product quality reviewer and regulatory researcher in the laboratory of Dr. Deborah Hursh. 

Dr. Eisenstatt's IOTF Experience

“The IOTF fellowship has provided a unique opportunity to shift focus from basic research to regulatory-driven research and product development. The seminars and trainings allow you to dive into the regulatory review process and the scientific research conducted at the FDA and to see how interconnected the two are. Working one-on-one with an experienced mentor provides a hands-on opportunity to learn how to review documents. During the review process, you can also interact with other experts at the FDA, which will help to build your knowledge of new topics and your network. The fellowship is an excellent experience for someone looking to continue to be engaged in novel scientific approaches and to learn about the drug development review process."


Katherine Elfer, Ph.D., MPH

As a CPFP-IOTF fellow, I have access to training in the full scope of medical device development, from ideation through regulatory approval. This unique vantage point provides better understanding of the avenues and gaps in translating novel technology from the laboratory to the hands of medical doctors and communities. My experience provides access to international collaborative communities all working on the same problem from different perspectives. Dr. Gallas, my mentor, has worked with me to develop a one-of-a-kind training program in project management, regulatory science, and regulatory review tailored to my career goals and housed in a supportive and invigorating research environment.

Dr. Elfer was awarded her Ph.D. in Biomedical Engineering from Tulane University in 2018 as a National Science Foundation Graduate Research Fellow. She then earned her Master’s in Public Health from Johns Hopkins University Bloomberg School of Public Health through the NCI Cancer Prevention Fellowship Program (CPFP). Following her MPH, Dr. Elfer joined Track 4 of the NCI-FDA Interagency Oncology Task Force Fellowship (IOTF) in October 2020 under the mentorship of Dr. Brandon Gallas of CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability.

Dr. Elfer's IOTF Experience

“As a CPFP-IOTF fellow, I have access to training in the full scope of medical device development, from ideation through regulatory approval. This unique vantage point provides better understanding of the avenues and gaps in translating novel technology from the laboratory to the hands of medical doctors and communities. My experience provides access to international collaborative communities all working on the same problem from different perspectives. Dr. Gallas, my mentor, has worked with me to develop a one-of-a-kind training program in project management, regulatory science, and regulatory review tailored to my career goals and housed in a supportive and invigorating research environment.”

 

Catherine Fischer, Ph.D., MPH

The IOTF Fellowship has been an invaluable opportunity to conduct critical research to advance FDA’s regulatory mission. The most unique aspect of the fellowship is the ability to gain first-hand experience in regulatory science within the agency through mentored reviewer training. The fellowship has also enabled me to build interdisciplinary collaborations throughout FDA, even in a predominately virtual environment.

Dr. Fischer received her Ph.D. in Pathobiology at the Johns Hopkins University School of Medicine. She then joined the Cancer Prevention Fellowship Program at the National Cancer Institute in 2019 and went on to receive her MPH at the Johns Hopkins School of Public Health. Dr. Fischer joined the NCI-FDA Interagency Oncology Task Force Fellowship in September 2020 in the laboratory of Dr. Rosalie Elespuru

Dr. Fischer's IOTF Experience

“The IOTF Fellowship has been an invaluable opportunity to conduct critical research to advance FDA’s regulatory mission. The most unique aspect of the fellowship is the ability to gain first-hand experience in regulatory science within the agency through mentored reviewer training. The fellowship has also enabled me to build interdisciplinary collaborations throughout FDA, even in a predominately virtual environment”

 

Nina Kim, M.D.

I have had the unique opportunity to learn the inner-workings of the FDA and learn how the FDA evaluates new protocols and drug applications.  Learning to perform comprehensive reviews of regulatory applications with a highly experienced mentor has been a unique benefit of this program.  I participated in the inaugural FDA-AACR fellowship, which was an incredible learning experience.

Dr. Kim received her M.D. at the Albert Einstein College of Medicine.  She completed 3 years of residency training in internal medicine at the Mount Sinai Hospital, Icahn School of Medicine campus in New York City.  She is now completing her clinical fellowship I hematology and medical oncology at the National Cancer Institute (NCI) and National Heart, Lung and Blood Institute.  She joined the NCI-FDA Interagency Oncology Task Force fellowship in October 2020 as a clinical reviewer in CDER, Office of Oncologic Diseases with Dr. Kelly Norsworthy as her primary mentor.

Dr. Kim's IOTF Experience

“I have had the unique opportunity to learn the inner-workings of the FDA and learn how the FDA evaluates new protocols and drug applications.  Learning to perform comprehensive reviews of regulatory applications with a highly experienced mentor has been a unique benefit of this program.  I participated in the inaugural FDA-AACR fellowship, which was an incredible learning experience.


Alumni Fellows

Here is a list of IOTF fellows, listed by cohort year.

Emine Guven- Maiorov, Ph.D.

Dr. Guven Maiorov received her B.Sc. in Molecular Biology and Genetics at Bogazici University and her M.Sc. and Ph.D. in Chemical and Biological Engineering at the Koc University, Istanbul/Turkey.  She then performed 3.5 years of post-doctoral training in the laboratory of Dr. Ruth Nussinov in the Cancer Inflammation Program at the National Cancer Institute.  Dr. Guven Maiorov joined the IOTF Fellowship in 2019 as a product quality research/review fellow in the laboratory of Dr. Wendy Weinberg.  In Dr. Weinberg’s lab, she utilizes computational approaches to evaluate the structural determinants and interactions between p63 – a p53 homologue – and downstream effector molecules to determine the 3D structure of protein-protein interaction complexes relevant to tumorigenesis and sensitivity/resistance to cancer therapeutics. She is also analyzing biotechnology products, such as monoclonal antibodies, to link to observed adverse events for elucidation of molecular mechanism(s).  Her long-term career goal is to continue to work as a full-time reviewer at FDA and contribute to FDA’s public health mission by assuring safety, efficacy, and quality of drugs and biologics.

Ancy Nalli, Ph.D.

Dr. Nalli received her Ph.D. in Physiology with a concentration in Molecular Biology and Genetics at Virginia Commonwealth University in Richmond, VA. After graduation, she completed three years of post-doctoral training in the Molecular Targets Program at the National Cancer Institute.  There she studied the role of small molecule therapeutics to sensitize resistant cancer cells to Tumor Necrosis Factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.  Dr. Nalli joined the IOTF Fellowship in September 2018 as a product quality research/review fellow, where she studies the development of cell-based assays to evaluate the bioactivity of reference materials for the TNF-alpha blocker, adalimumab.  Her work is as part of an international collaborative study with the World Health Organization (WHO) to develop the 1st international standard (IS) for adalimumab.  Her long-term career goal is to become a product quality reviewer for biotechnology products.

2018

  • Qiong Fu, Ph.D.
  • Michael Moses

2017

  • Danielle Brooks, Ph.D.
  • Andrew Harmon, Ph.D.
  • Elizabeth Lessey Morillon, Ph.D.
  • Jun Zhao, Ph.D.

2016

  • Andrea George, Ph.D.
  • Karol Szczepanek, Ph.D.
  • Mayumi Takahashi, Ph.D.

2015

  • Ekaterina Allen, Ph.D.
  • Aysegul Ergen, Ph.D.
  • Anna Kwilas, Ph.D.
  • Sandhya Sanduja, Ph.D.
  • Nailing Zhang

See more IOTF Alumni from 2009-2014.

 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Current and Alumni Fellows was originally published by the National Cancer Institute.”